Here w e describe a new platelet-specific alloantigen that was identified in a case of neonatal alloimmune thrombocytopenia. This antigen has provisionally been called "Mo." By studying the Mo family, it was shown to be inherited in an autosomal dominant manner. Immunoprecipitation and Western blot analysis showed that the antigen resides on platelet glycoprotein Ilia (GP Ilia). Genomic analysis, performed by applying polymerase chain reaction and sequencing, showed a C + G substitution of base pair 1267 of the coding region of the DNA for GP Ilia, resulting in a substitution of Proline407 by Alaninea7. That this substitution is associated with the antigen could be demonstrated HE FIRST platelet-specific alloantigen system Zw = T HPA-I was discovered by van Loghem et all in 1959 in a case of posttransfusion purpura (PTP). Since then, many more platelet alloantigen systems have been described involved in PTP and/or neonatal alloimmune thrombocytopenia (NAIT).2-6 To date, five alloantigen systems are generally recognized and named HPA-I to HPA-5 (HPA, human platelet antigen).' Recently, an important advance in the understanding of the nature of platelet-specific alloantigens was achieved by Newman et al,' who showed that the HPA-I antigens (Zw/PIA) are associated with a C -P T point mutation in the DNA coding for glycoprotein IIIa (GP Ma), resulting in a substitution of Leucine33 by Proline33 in HPA-la and -b, respectively. Subsequently, the HPA-2, -3, and -4 systems were also proven to be associated with single point mutations of the DNA coding for GP Iba, GP IIb, and GP IIIa, respectively, resulting in single amino acid polymorphisms?-" Thus, it has become possible to type for these polymorphisms at the genomic level.
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MATERIALS AND METHODS
The family in which this case of NAIT occurred will be called Mo. After an uneventful second pregnancy, a boy was born to a healthy mother. The APGAR scores were 9 and IO after 1 and 5 minutes, respectively. Petechiae developed 3 hours postpartum; otherwise the boy was healthy. There were no signs of infection and on physical examination there was no hepatomegaly or splenomegaly. The petechiae worsened and the boy was admitted to a neonatal intensive care unit with extensive hematomas. Four hours after delivery he vomited fresh and old blood. There also was meleana with fresh blood admixed. Laboratory investigation at that time showed a hemoglobin (Hb) count of 13.1 mmol/L, hematocrit (Ht) 0.6 1, leukocyte count 36.6 X 106/L (differential 86% neutrophils, from which 26% were stabs, 5% lymphocytes, 8% monocytes and 1% eosinophils). Activated partial thromboplastin time (APTT) was 34.2 seconds, PTT 12.6 seconds, fibrinogen 2.1 g/L, and platelets 3 X IO9/ L. Because of the leukocytosis with 26% stabs in combination with thrombocytopenia, he was suspected of having a septicemia and treated with antibiotics. However, during the next 2 days the platelet count did not increase. Blood cultures remained negative. Gastrointestinal tract bleedings were most pronounced during the first 2 days, for which recurrent washings with cold saline were performed. Under suspicion of a neonatal alloimmune thrombocytopenia, he was given a transfusion of maternal platelets, from which the maternal plasma had been removed and substituted by normal donor plasma. After transfusion, the platelet count was 56 X 109/L. When the platelet count decreased to I5 X 109/L the following day, he was treated with high-dose intravenous Ig (IVIg) (0.4 g/kg) for 3 days. The platelet count stabilized and started to increase slowly to 46 X IO9 in the following weeks. There were no signs of intracranial bleedings and an echography of the brain showed no abnormalities. The first child of these parents was born healthy and had not shown signs of an increased bleeding tendency. At the first control in the outpatient clinic, the platelet count was 3 1 1.
Blood samples from both parents and the child and later also from different family members were analyzed. The platelets of the parents were typed for platelet alloantigens to show potential incompatibilities. The following antisera were used: anti-HPA-1 a (IgG-anti-Zwa/PIA'), anti-HPA-1 b (IgG-anti-Zg/Pl*'), serum 1072 containing IgM alloantibodies against the HPA-2b antigens, and serum 9725 containing IgM alloantibodies against the HPA-2a antigen, anti-HPA-3a (IgG-anti-Bak"), anti-HPA-3b (IgG-anti-Bakb), and anti-Sr (IgG-anti&"). The latter two sera were gifts from Prof Dr Mueller-Eckhardt (Giessen, Germany). As a negative control serum, the serum of a nontransfused male with blood-group AB was Case report.
Blood.
PLATELET-SPECIFIC ALLOANTIGEN Mo" 71 Monoclonal antibodies (MoAbs). The following MoAbs were used MB45, CD42b against GP Iba; CLB-thromb/l (C17), CD61 against GP IIIa; CLB-thromb/4 (IOGl I), CD49b against VLA a2chain; Y2/5I, CD61 against GP IIIa; MB9, CD41 against GP IIb; SW16, an MoAb against platelet GP V.I3 All MoAbs except SW16 have been described el~ewhere.'~ Platelets and the indirect platelet immunofluorescence test (PIFT). Determination of the phenotype on platelets was performed by PIFI on chloroquine-treated platelets as described before,15 except for HPA-Sa and b, which were tested for in the MAIPA (see below).
The MAIPA was performed according to Kiefel et all6 with minor modifications. In a typical experiment, 5 X lo6 freshly isolated packed platelets were resuspended in 50 pL of an appropriate dilution of MoAbs together with 40 p L of human serum and incubated for 30 minutes at 37°C. The cells were then washed three times in phosphatebuffered saline/bovine serum albumin (PBS/BSA). After pelleting, the platelets were solubilized in 50 pL ice-cold Tris buffer (50 mmol/ L Tris-HC1, 150 mmol/L NaC1, pH 7.4) supplemented with 1% NP-40 (wt/vol) for 30 minutes at 4°C. To remove unsolubilized material, the lysate was centrifuged at 13,OOOg for 30 minutes at 4°C. Thirtyfive microliters of supernatant was collected and transferred into 150 pL of ice-cold incubation buffer (Tris buffer supplemented with I% NP-40 [wt/vol], 0.05% Tween-20 [vol/vol], and 0.2% BSA [wt/vol]). Fifty microlitem thereof was placed in triplicate in the wells of a microtiter plate (Maxisorp; Nunc, Roskilde, Denmark) precoated with goat-anti-mouse Ig (7.5 g/mL; Jackson Immunoresearch, West Grove, PA) in 0.1 mol/L NaHC03/Na2C03, pH 9.6, overnight at 4°C. The plate was incubated overnight at 4°C. After five washings, 50 pL alkaline phosphatase-conjugated goat-anti-human IgG or IgM antibodies (Jackson), diluted in incubation buffer, was placed in the MoAb immobilization of platelet antigen assay (MAIPA). (H). not tested. wells and incubated for 2 hours at 4"C, followed by another five washings. Finally, the bound conjugate was demonstrated by adding Sigma-104 phosphatase substrate (Sigma Chemicals, St Louis, MO) dissolved in diethanolamine buffer, pH 10. The extinction was measured in a Titertek reader (ITK Diagnostics BV, Uithoorn, The Netherlands) at 405 nm.
Immunoprecipitation. and iodogen as catalyst, were incubated with 50 pL of human serum or 50 pL of MoAb. The platelets were subsequently washed three times in PBS/BSA and solubilized in 100 pL of immunoprecipitation buffer (IPB) containing 50 mmol/L Tris-HCI, 150 mmol/L NaCI, 1% NP-40 (wt/vol), supplemented with 5 mmol/L EDTA, 1 mmol/ L phenylmethylsulfonyl fluoride (PMSF), 0.02 mg/mL trypsin inhibitor, and 5 mmol/L N-ethylmaleimide (NEM) for 30 minutes at 4°C. The lysate was centrifuged for 30 minutes at 13,OOOg at 4°C. Fifty microliters of a 10% suspension of polyclonal goat-anti-mouse Ig (CLB, GM 17D) or MoAb mouse-anti-human IgG (CLB MH16-1) covalently linked to Sepharose-4B beads (Pharmacia Fine Chemicals AB, Uppsala, Sweden) were added to the lysate and incubated for 3 hours at 4°C. The beads were washed three times with IPB at 4°C. The pellet was resuspended in 50 pL of sodium dodecyl sulfate (SDS) sample mix and heated at 95°C for 5 minutes. The precipitated proteins were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) on 7.5% polyacrylamide gels.'' The gels were dried and autoradiographed with the help of an intensifier screen.
Platelets for immunoblotting analysis were washed and solubilized in a buffer composed of 20 mmol/L Tris-HC1, 150 mmol/L NaC1, 10 mmol/L EDTA, 5 mmol/L NEM, 1 mmol/L PMSF, and trypsin inhibitor (0.02 mg/mL). The lysates were centrifuged at 13,OOOg for 30 minutes. The platelet proteins were separated on 7.5% SDS-PAGE under nonreducing conditions and subsequently electrophoretically transferred to nitrocellulose according to Towbin (1979) ." The blot was then preincubated for 1 hour at room temperature in PBS with 3% fetal calf serum (FCS) and cut into strips. The strips were incubated with the different sera (1:20) diluted in 10 mmol/L Tris-HCI, 150 mmol/L NaCl, 0.05% Tween-20 (pH 8.0) [TBST]), or the MoAbs (1500 diluted also in TBST), and were washed three times with TBST. Second incubations were with alkaline phosphatase-conjugated goat-anti-human IgG or alkaline phosphatase-conjugated goat-anti-mouse IgG ( 1 :7,500; Promega, Madison, wl). The nitrocellulose strips were washed three times again with TBST. The alkaline phosphate reaction was visualized by using the Proto Blot immunoscreening system (Promega) with nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphate (BCIP) as substrates.
Platelets, 5 X IO8, radiolabeled with Western blotting.
1'
For personal use only. on October 30, 2017. by guest www.bloodjournal.org primer annealing at 62°C. and a 2%minute extension at 72°C. Amplified fragments were purified by agarose electrophoresis, cleaved with the Ilindlll and EcoRl restriction endonucleases and were inserted into puc 18 with T4 DNA ligase. The insertcontaining puc-I8 preparations were used to transform DHSa Escherichia coli competent cells in the presence of ampicillin and X-gal. Nucleotide sequences were determined by the dideoxy-chain-termination method using Sequenase according to the manufacturers' recommendations (US Biochemical Cop, Cleveland, OH). Bsp-1286 restriction digestions were performed under conditions recommended by the manufacturers (Biolabs, New England, Beverly, MA). Furthermore, we performed, with overlapping sets of primer DNA, analysis of the entire G P llla molecule; from all regions, at least six nucleotide sequences were determined.
Allele-specific oligonircleotide dot-blot hybridization to amplified DNA. Allele-specific oligonucleotides in this study had nucleotide sequences 5' GGCTGTCCCCAGG 3' (probe A), 5' GGCTGT-GCCCAGG 3' (probe B). as discussed later. Oligonucleotides were radiolabeled using [y-'zP)adenosine triphosphate (ATP) and T4 polynucleotide kinase (Boehringer, Mannheim, Germany). After PCR, IO-pL portions of the reaction mixtures were diluted with 100 pL of water and boiled for 3 minutes, whereafter I IO pL, 20 times 
RESULTS
The phenotyping of the parents' platelets showed no incompatibilities for HPA-I, -2, -3, or
sf?rOlOf$C inve.VigcNions.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org -5 alloantigens. The results are shown in Table I . The direct test on platelets of the mother was weakly positive using an anti-Ig or an anti-IgM conjugate but negative with an anti-IgG conjugate. Cross-matching with maternal serum and paternal platelets gave strongly positive results, also after chloroquine treatment (which dissociates HLA antigens of the surface of the platelets). These antibodies were of the IgG class. The Mo serum did not react with any of the typed panel platelets, suggesting the presence of alloantibodies against a private or a low-frequency antigen.
To investigate the Occurrence of the Mo antigen in the family, platelets from the available family members were tested in the PRT.
Family sfudy. The Mo family tree is depicted in Fig 1. As shown in this figure, all 9 members of the first generation, 14 members of the second generation, and 5 members of the third generation, to which the propositus belongs, could be studied. All members of this large family were healthy and none had a history of a bleeding tendency or a tendency for thrombosis and/or embolism. There was no previous case of NAIT in the family. Routine blood counts were normal. From the segregation pattem in the family, it can be concluded that the Mo antigen is inherited as an autosomal dominant allele ( Fig I) . Because all members ofthe family were HPA-I (a+, b-), an association with the HPA-I antigens cannot be excluded or proven. There is no apparent coinheritance with any of the other HPA antigens tested and there is no relation with the Sr private antigen.'* The results of the MAIPA localize the Mo antigen on G P IIb/IIIa, because the maternal serum gave strongly positive reactions in combination with C17 (MoAb against GP IIb/IIIa) when tested with paternal platelets, whereas with the other MoAbs (MB45, lOGl1, MB9, SW16) the results were negative. Typing results in the Mo family in the MAIPA were in concordance with those obtained in the PFIT.
To further localize the Mo antigen we performed immunoprecipitation and Western blotting. The Mo antibodies precipitated predominantly G P IIIa (Fig 2) . Although GP IIb could be precipitated from the lysate by specific antibodies, few GP IIb were coprecipitated by the Mo antibodies. Dissociative conditions during the precipitation together with a poorer iodine labeling of G P Ilb probably contributed to this. However, the immunoblotting experiments demonstrate more unequivocally that an epitope on GP IIIa is recognized by the Mo antibodies (Fig 2) .
Immunochemical invesfigations.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org RFLP anulysis. The C + G Substitution Created a KCognition site for the restriction enzyme BSp 1286, which cleaves at 5'43TGCCC-3' but not at 5'43TccCC-3' sequences.
Digestion of the PCR fragments (primers 1 and 2) with BSP I286 yielded the fragments of expected size (Fig 3) .
For family analysis on genomic DNA, we used primers Id and 2, which yielded a PCR fragment of 228 bp. From the mononuclear leukocytes of seven family members (four Mo" and three Moa-), genomic DNA was isolated, amplified, and restriction fragment length polymorphism WW analysis was performed with Bsp 1286. The results after digestion were in agreement with those ofthe RFLP analysis performed on cDNA (Fig 4) .
Allele-spec$c oligonucleotide (ASO) analysis. AS0 typing using dot-blot hybridization analysis was also performed, using oligonucleotide probes specific for the Moa-and Moa+ sequence to probe the PCR products of cDNA and genomic DNA, from six Moa+ and two Moa-family donors (Fig 5) .
These data were fully concordant with the RFLP analysis results.
Until now, we have tested 450 random blood donors for expression of the Mo antigen. Initially, typing was performed in the PlFT and MAIPA techniques. One of them appeared to be positive for the Mo antigen; this was confirmed by DNA analysis. This implies that Moa is a low-frequency antigen.
DISCUSSION
Alloimmunization ofa mother by fetal platelet-speCific alloantigens may provoke a fetal and/or neonatal alloimmune thrombocytopenia. Most commonly, alloantibodies against HPA-la are involved. Recently, alloantibodies against a -private-piatelet alloantigen -sra*3 were described by b l l et aI.l2 Here we report a new "private" platelet alloantigen involved in NAIT, different from Sr', called M o ' .
We identified the platelet glycoprotein on which this Mo' antigen resides to be GP IIIa by means of MAIPA, immunoprecipitation, and immunoblotting. Introduction of molecular biologic techniques has given insight in the genetic basis of platelet alloantigen systems. So far, four systems have been shown to be associated with single base-pair substitutions in the coding DNA for their respective glycoproteins. Because the possibility existed that more than one amino acid substitution may be responsible in the formation of an alloantigen, we sequenced the entire coding region of G P Illa. As the only difference with the published sequence20*2' and with that of a control donor, we found a C -G substitution at base pair 1267 of the mature DNA giving rise to a Proline"/ Alanine" polymorphism. This could be demonstrated by direct sequencing of the G P llla cDNA. The presence of the For personal use only. on October 30, 2017. by guest www.bloodjournal.org From 76 KUIJPERS ET AL mutation could also be shown by RFLP analysis of the by PCR-obtained fragments derived either from cDNA or genomic DNA. Because there is only one amino acid substitution in the entire GP IIIa, we believe that this is the cause of the antigenicity of the Mo antigen. However, the antigenic epitope does not need to be identical.
The alloantigen "Mo" has a restricted population expression; ie, only one unrelated donor was found to be positive. This was shown by classical serologic methods as well as by DNA analysis.
Because none of the family members positive for the Moa antigen had signs of an altered hemostasis, it seems likely that heterozygosity does not affect the physiologic function of GP IIb/IIIa. However, it is notable that of the nine platelet alloantigen systems described thus far, five, including the Moa antigen, reside on GP IIb/IIla. It seems that in vivo mutagenesis does not per se lead to clinically noticeable platelet dysfunction. However, more detailed analysis may show more subtle dysfunctions. The genomic basis of the antigen polymorphisms makes such studies feasible.
In conclusion, we describe a new platelet alloantigen that was identified in a case of NAIT on membrane glycoprotein IIIa.
